#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=We noted a constant increase in the incidence of IE in Spain , principally because of a dramatic rise in the proportion of NIE concurrent with a decline in the percentage of CIE .
3-1	15-17	We	person	acc	ana	15-1
3-2	18-23	noted	_	_	_	_
3-3	24-25	a	abstract[4]	new[4]	coref	8-18[50_4]
3-4	26-34	constant	abstract[4]	new[4]	_	_
3-5	35-43	increase	abstract[4]	new[4]	_	_
3-6	44-46	in	abstract[4]	new[4]	_	_
3-7	47-50	the	abstract[4]|abstract[5]	new[4]|new[5]	coref	5-4[21_5]
3-8	51-60	incidence	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-9	61-63	of	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-10	64-66	IE	abstract[4]|abstract[5]|object[6]	new[4]|new[5]|new[6]	coref	8-9[0_6]
3-11	67-69	in	abstract[4]|abstract[5]|object[6]	new[4]|new[5]|new[6]	_	_
3-12	70-75	Spain	abstract[4]|abstract[5]|object[6]|place	new[4]|new[5]|new[6]|new	coref	8-27
3-13	76-77	,	_	_	_	_
3-14	78-89	principally	event[8]	new[8]	coref	22-1[184_8]
3-15	90-97	because	event[8]	new[8]	_	_
3-16	98-100	of	event[8]	new[8]	_	_
3-17	101-102	a	event[8]	new[8]	_	_
3-18	103-111	dramatic	event[8]	new[8]	_	_
3-19	112-116	rise	event[8]	new[8]	_	_
3-20	117-119	in	event[8]	new[8]	_	_
3-21	120-123	the	event[8]|quantity[9]	new[8]|new[9]	_	_
3-22	124-134	proportion	event[8]|quantity[9]	new[8]|new[9]	_	_
3-23	135-137	of	event[8]|quantity[9]	new[8]|new[9]	_	_
3-24	138-141	NIE	event[8]|quantity[9]|abstract[10]	new[8]|new[9]|new[10]	coref	4-1[0_10]
3-25	142-152	concurrent	event[8]|quantity[9]|abstract[10]	new[8]|new[9]|new[10]	_	_
3-26	153-157	with	_	_	_	_
3-27	158-159	a	event[11]	new[11]	coref	20-10[148_11]
3-28	160-167	decline	event[11]	new[11]	_	_
3-29	168-170	in	event[11]	new[11]	_	_
3-30	171-174	the	event[11]|quantity[12]	new[11]|new[12]	_	_
3-31	175-185	percentage	event[11]|quantity[12]	new[11]|new[12]	_	_
3-32	186-188	of	event[11]|quantity[12]	new[11]|new[12]	_	_
3-33	189-192	CIE	event[11]|quantity[12]|abstract	new[11]|new[12]|new	coref	4-6
3-34	193-194	.	_	_	_	_

#Text=NIE showed higher morbidity than CIE , as elderly patients were the most affected group .
4-1	195-198	NIE	abstract	giv	coref	6-27[35_0]
4-2	199-205	showed	_	_	_	_
4-3	206-212	higher	abstract[15]	new[15]	_	_
4-4	213-222	morbidity	abstract[15]	new[15]	_	_
4-5	223-227	than	abstract[15]	new[15]	_	_
4-6	228-231	CIE	abstract[15]|abstract	new[15]|giv	coref	5-6
4-7	232-233	,	_	_	_	_
4-8	234-236	as	_	_	_	_
4-9	237-244	elderly	person[17]	new[17]	coref	4-12[18_17]
4-10	245-253	patients	person[17]	new[17]	_	_
4-11	254-258	were	_	_	_	_
4-12	259-262	the	person[18]	giv[18]	coref	11-10[76_18]
4-13	263-267	most	person[18]	giv[18]	_	_
4-14	268-276	affected	person[18]	giv[18]	_	_
4-15	277-282	group	person[18]	giv[18]	_	_
4-16	283-284	.	_	_	_	_

#Text=The North reported the highest CIE incidence .
5-1	285-288	The	place[19]	new[19]	coref	26-15[220_19]
5-2	289-294	North	place[19]	new[19]	_	_
5-3	295-303	reported	_	_	_	_
5-4	304-307	the	abstract[21]	giv[21]	_	_
5-5	308-315	highest	abstract[21]	giv[21]	_	_
5-6	316-319	CIE	abstract|abstract[21]	giv|giv[21]	coref	6-30
5-7	320-329	incidence	abstract[21]	giv[21]	_	_
5-8	330-331	.	_	_	_	_

#Text=Cox regression analysis revealed that age , Charlson index , hemodialysis , shock , heart failure , and stroke were independent risk factors of mortality for both NIE and CIE .
6-1	332-335	Cox	person|abstract[24]	new|new[24]	_	_
6-2	336-346	regression	abstract|abstract[24]	new|new[24]	_	_
6-3	347-355	analysis	abstract[24]	new[24]	_	_
6-4	356-364	revealed	_	_	_	_
6-5	365-369	that	substance[25]	new[25]	appos	6-8[27_25]
6-6	370-373	age	substance[25]	new[25]	_	_
6-7	374-375	,	_	_	_	_
6-8	376-384	Charlson	person|abstract[27]	new|giv[27]	coref|coref	21-5[164_27]|21-5[164_27]
6-9	385-390	index	abstract[27]	giv[27]	_	_
6-10	391-392	,	abstract[27]	giv[27]	_	_
6-11	393-405	hemodialysis	abstract[27]	giv[27]	_	_
6-12	406-407	,	abstract[27]	giv[27]	_	_
6-13	408-413	shock	abstract[27]|event	giv[27]|new	coref	21-39
6-14	414-415	,	abstract[27]	giv[27]	_	_
6-15	416-421	heart	abstract[27]|object|event[30]	giv[27]|new|new[30]	coref|coref|coref|coref	21-41|21-41[179_30]|21-41|21-41[179_30]
6-16	422-429	failure	abstract[27]|event[30]	giv[27]|new[30]	_	_
6-17	430-431	,	abstract[27]	giv[27]	_	_
6-18	432-435	and	abstract[27]	giv[27]	_	_
6-19	436-442	stroke	abstract[27]|event	giv[27]|new	_	_
6-20	443-447	were	_	_	_	_
6-21	448-459	independent	abstract[33]	new[33]	_	_
6-22	460-464	risk	abstract|abstract[33]	new|new[33]	coref	24-42[205_0]
6-23	465-472	factors	abstract[33]	new[33]	_	_
6-24	473-475	of	abstract[33]	new[33]	_	_
6-25	476-485	mortality	abstract[33]|abstract[34]	new[33]|new[34]	coref	24-46[206_34]
6-26	486-489	for	abstract[33]|abstract[34]	new[33]|new[34]	_	_
6-27	490-494	both	abstract[33]|abstract[34]|abstract[35]	new[33]|new[34]|giv[35]	coref	10-5[0_35]
6-28	495-498	NIE	abstract[33]|abstract[34]|abstract[35]	new[33]|new[34]|giv[35]	_	_
6-29	499-502	and	abstract[33]|abstract[34]	new[33]|new[34]	_	_
6-30	503-506	CIE	abstract[33]|abstract[34]|abstract	new[33]|new[34]|giv	coref	7-21
6-31	507-508	.	_	_	_	_

#Text=In addition , the female sex , renal disease , and use of pacemakers or defibrillators were mortality-associated factors of CIE .
7-1	509-511	In	_	_	_	_
7-2	512-520	addition	_	_	_	_
7-3	521-522	,	_	_	_	_
7-4	523-526	the	abstract[37]	new[37]	_	_
7-5	527-533	female	abstract[37]	new[37]	_	_
7-6	534-537	sex	abstract[37]	new[37]	_	_
7-7	538-539	,	_	_	_	_
7-8	540-545	renal	abstract|abstract[39]	new|new[39]	coref|coref	16-16[116_39]|16-16[116_39]
7-9	546-553	disease	abstract[39]	new[39]	_	_
7-10	554-555	,	_	_	_	_
7-11	556-559	and	_	_	_	_
7-12	560-563	use	abstract[40]	new[40]	coref	7-18[43_40]
7-13	564-566	of	abstract[40]	new[40]	_	_
7-14	567-577	pacemakers	abstract[40]|object	new[40]|new	_	_
7-15	578-580	or	abstract[40]	new[40]	_	_
7-16	581-595	defibrillators	abstract[40]|object	new[40]|new	_	_
7-17	596-600	were	_	_	_	_
7-18	601-621	mortality-associated	abstract[43]	giv[43]	coref	21-2[162_43]
7-19	622-629	factors	abstract[43]	giv[43]	_	_
7-20	630-632	of	abstract[43]	giv[43]	_	_
7-21	633-636	CIE	abstract[43]|abstract	giv[43]|giv	_	_
7-22	637-638	.	_	_	_	_

#Text=Numerous studies have confirmed a rising trend of IE rates over time . Olmos et al. found a significant increase in the incidence of IE in Spain from 2003 to 2014 .
8-1	639-647	Numerous	event[45]	new[45]	coref	17-24[127_45]
8-2	648-655	studies	event[45]	new[45]	_	_
8-3	656-660	have	_	_	_	_
8-4	661-670	confirmed	_	_	_	_
8-5	671-672	a	abstract[46]	new[46]	coref	14-1[95_46]
8-6	673-679	rising	abstract[46]	new[46]	_	_
8-7	680-685	trend	abstract[46]	new[46]	_	_
8-8	686-688	of	abstract[46]	new[46]	_	_
8-9	689-691	IE	abstract[46]|object|abstract[48]	new[46]|giv|new[48]	coref|coref|coref|coref	8-25[52_0]|22-32[193_48]|8-25[52_0]|22-32[193_48]
8-10	692-697	rates	abstract[46]|abstract[48]	new[46]|new[48]	_	_
8-11	698-702	over	abstract[46]|abstract[48]	new[46]|new[48]	_	_
8-12	703-707	time	abstract[46]|abstract[48]	new[46]|new[48]	_	_
8-13	708-709	.	_	_	_	_
8-14	710-715	Olmos	person	new	_	_
8-15	716-718	et	_	_	_	_
8-16	719-722	al.	_	_	_	_
8-17	723-728	found	_	_	_	_
8-18	729-730	a	abstract[50]	giv[50]	coref	10-10[67_50]
8-19	731-742	significant	abstract[50]	giv[50]	_	_
8-20	743-751	increase	abstract[50]	giv[50]	_	_
8-21	752-754	in	abstract[50]	giv[50]	_	_
8-22	755-758	the	abstract[50]|abstract[51]	giv[50]|new[51]	_	_
8-23	759-768	incidence	abstract[50]|abstract[51]	giv[50]|new[51]	_	_
8-24	769-771	of	abstract[50]|abstract[51]	giv[50]|new[51]	_	_
8-25	772-774	IE	abstract[50]|abstract[51]|object[52]	giv[50]|new[51]|giv[52]	coref	9-11[0_52]
8-26	775-777	in	abstract[50]|abstract[51]|object[52]	giv[50]|new[51]|giv[52]	_	_
8-27	778-783	Spain	abstract[50]|abstract[51]|object[52]|place	giv[50]|new[51]|giv[52]|giv	coref	26-1[215_0]
8-28	784-788	from	_	_	_	_
8-29	789-793	2003	time	new	_	_
8-30	794-796	to	_	_	_	_
8-31	797-801	2014	time	new	_	_
8-32	802-803	.	_	_	_	_

#Text=Similarly , Bor et al. reported the rising number of IE episodes is due to Staphylococcus aureus infections associated with cardiac devices and implants .
9-1	804-813	Similarly	_	_	_	_
9-2	814-815	,	_	_	_	_
9-3	816-819	Bor	person	new	_	_
9-4	820-822	et	_	_	_	_
9-5	823-826	al.	_	_	_	_
9-6	827-835	reported	_	_	_	_
9-7	836-839	the	event[57]	new[57]	_	_
9-8	840-846	rising	event[57]	new[57]	_	_
9-9	847-853	number	event[57]	new[57]	_	_
9-10	854-856	of	event[57]	new[57]	_	_
9-11	857-859	IE	event[57]|object|abstract[59]	new[57]|giv|new[59]	coref|coref|coref|coref	11-7|15-28[111_59]|11-7|15-28[111_59]
9-12	860-868	episodes	event[57]|abstract[59]	new[57]|new[59]	_	_
9-13	869-871	is	_	_	_	_
9-14	872-875	due	_	_	_	_
9-15	876-878	to	_	_	_	_
9-16	879-893	Staphylococcus	object|abstract[62]	new|new[62]	coref|coref|coref|coref	20-41[157_62]|30-20|20-41[157_62]|30-20
9-17	894-900	aureus	object|abstract[62]	new|new[62]	_	_
9-18	901-911	infections	abstract[62]	new[62]	_	_
9-19	912-922	associated	_	_	_	_
9-20	923-927	with	_	_	_	_
9-21	928-935	cardiac	object[63]	new[63]	_	_
9-22	936-943	devices	object[63]	new[63]	_	_
9-23	944-947	and	_	_	_	_
9-24	948-956	implants	object	new	_	_
9-25	957-958	.	_	_	_	_

#Text=The growing incidence of NIE could be related to the increase in the prevalence of healthcare-associated interventional procedures in recent years ( e. g. , hemodialysis , catheterization , intravenous line placement , cardiac implantable electronic devices , prostheses ) .
10-1	959-962	The	abstract[65]	new[65]	_	_
10-2	963-970	growing	abstract[65]	new[65]	_	_
10-3	971-980	incidence	abstract[65]	new[65]	_	_
10-4	981-983	of	abstract[65]	new[65]	_	_
10-5	984-987	NIE	abstract[65]|abstract	new[65]|giv	coref	15-10
10-6	988-993	could	_	_	_	_
10-7	994-996	be	_	_	_	_
10-8	997-1004	related	_	_	_	_
10-9	1005-1007	to	_	_	_	_
10-10	1008-1011	the	abstract[67]	giv[67]	coref	14-11[97_67]
10-11	1012-1020	increase	abstract[67]	giv[67]	_	_
10-12	1021-1023	in	abstract[67]	giv[67]	_	_
10-13	1024-1027	the	abstract[67]|abstract[68]	giv[67]|new[68]	ana	11-3[0_68]
10-14	1028-1038	prevalence	abstract[67]|abstract[68]	giv[67]|new[68]	_	_
10-15	1039-1041	of	abstract[67]|abstract[68]	giv[67]|new[68]	_	_
10-16	1042-1063	healthcare-associated	abstract[67]|abstract[68]|abstract[69]	giv[67]|new[68]|new[69]	coref	13-24[91_69]
10-17	1064-1078	interventional	abstract[67]|abstract[68]|abstract[69]	giv[67]|new[68]|new[69]	_	_
10-18	1079-1089	procedures	abstract[67]|abstract[68]|abstract[69]	giv[67]|new[68]|new[69]	_	_
10-19	1090-1092	in	abstract[67]|abstract[68]|abstract[69]	giv[67]|new[68]|new[69]	_	_
10-20	1093-1099	recent	abstract[67]|abstract[68]|abstract[69]|time[70]	giv[67]|new[68]|new[69]|new[70]	coref	11-14[77_70]
10-21	1100-1105	years	abstract[67]|abstract[68]|abstract[69]|time[70]	giv[67]|new[68]|new[69]|new[70]	_	_
10-22	1106-1107	(	_	_	_	_
10-23	1108-1110	e.	_	_	_	_
10-24	1111-1113	g.	_	_	_	_
10-25	1114-1115	,	_	_	_	_
10-26	1116-1128	hemodialysis	_	_	_	_
10-27	1129-1130	,	_	_	_	_
10-28	1131-1146	catheterization	_	_	_	_
10-29	1147-1148	,	_	_	_	_
10-30	1149-1160	intravenous	_	_	_	_
10-31	1161-1165	line	object	new	_	_
10-32	1166-1175	placement	_	_	_	_
10-33	1176-1177	,	_	_	_	_
10-34	1178-1185	cardiac	person	new	_	_
10-35	1186-1197	implantable	abstract	new	_	_
10-36	1198-1208	electronic	_	_	_	_
10-37	1209-1216	devices	_	_	_	_
10-38	1217-1218	,	_	_	_	_
10-39	1219-1229	prostheses	_	_	_	_
10-40	1230-1231	)	_	_	_	_
10-41	1232-1233	.	_	_	_	_

#Text=Furthermore , this probably explains why IE rose in those patients older than 80 years .
11-1	1234-1245	Furthermore	_	_	_	_
11-2	1246-1247	,	_	_	_	_
11-3	1248-1252	this	abstract	giv	_	_
11-4	1253-1261	probably	_	_	_	_
11-5	1262-1270	explains	_	_	_	_
11-6	1271-1274	why	_	_	_	_
11-7	1275-1277	IE	object	giv	coref	12-16
11-8	1278-1282	rose	_	_	_	_
11-9	1283-1285	in	_	_	_	_
11-10	1286-1291	those	person[76]	giv[76]	coref	13-29[93_76]
11-11	1292-1300	patients	person[76]	giv[76]	_	_
11-12	1301-1306	older	person[76]	giv[76]	_	_
11-13	1307-1311	than	_	_	_	_
11-14	1312-1314	80	time[77]	giv[77]	coref	22-28[191_77]
11-15	1315-1320	years	time[77]	giv[77]	_	_
11-16	1321-1322	.	_	_	_	_

#Text=Another factor explaining the consistently increasing pattern might be the changes in the prevention of IE .
12-1	1323-1330	Another	abstract[78]	new[78]	coref	12-10[80_78]
12-2	1331-1337	factor	abstract[78]	new[78]	_	_
12-3	1338-1348	explaining	_	_	_	_
12-4	1349-1352	the	abstract[79]	new[79]	_	_
12-5	1353-1365	consistently	abstract[79]	new[79]	_	_
12-6	1366-1376	increasing	abstract[79]	new[79]	_	_
12-7	1377-1384	pattern	abstract[79]	new[79]	_	_
12-8	1385-1390	might	_	_	_	_
12-9	1391-1393	be	_	_	_	_
12-10	1394-1397	the	abstract[80]	giv[80]	coref	24-37[204_80]
12-11	1398-1405	changes	abstract[80]	giv[80]	_	_
12-12	1406-1408	in	abstract[80]	giv[80]	_	_
12-13	1409-1412	the	abstract[80]|abstract[81]	giv[80]|new[81]	_	_
12-14	1413-1423	prevention	abstract[80]|abstract[81]	giv[80]|new[81]	_	_
12-15	1424-1426	of	abstract[80]|abstract[81]	giv[80]|new[81]	_	_
12-16	1427-1429	IE	abstract[80]|abstract[81]|object	giv[80]|new[81]|giv	coref	14-15
12-17	1430-1431	.	_	_	_	_

#Text=The American Heart Association in 2007 revised and changed the consensus for antibiotic prophylaxis , recommending the withdrawal of routine antibiotic prophylaxis for dental procedures in low-risk and moderate-risk patients and most other invasive procedures in all patients .
13-1	1432-1435	The	person[83]	new[83]	_	_
13-2	1436-1444	American	person[83]	new[83]	_	_
13-3	1445-1450	Heart	person[83]	new[83]	_	_
13-4	1451-1462	Association	person[83]	new[83]	_	_
13-5	1463-1465	in	person[83]	new[83]	_	_
13-6	1466-1470	2007	person[83]|time	new[83]|new	_	_
13-7	1471-1478	revised	_	_	_	_
13-8	1479-1482	and	_	_	_	_
13-9	1483-1490	changed	_	_	_	_
13-10	1491-1494	the	abstract[85]	new[85]	coref	20-53[0_85]
13-11	1495-1504	consensus	abstract[85]	new[85]	_	_
13-12	1505-1508	for	abstract[85]	new[85]	_	_
13-13	1509-1519	antibiotic	abstract[85]|substance|abstract[87]	new[85]|new|new[87]	coref|coref|coref|coref	13-21|13-20[90_87]|13-21|13-20[90_87]
13-14	1520-1531	prophylaxis	abstract[85]|abstract[87]	new[85]|new[87]	_	_
13-15	1532-1533	,	_	_	_	_
13-16	1534-1546	recommending	_	_	_	_
13-17	1547-1550	the	event[88]	new[88]	_	_
13-18	1551-1561	withdrawal	event[88]	new[88]	_	_
13-19	1562-1564	of	event[88]	new[88]	_	_
13-20	1565-1572	routine	event[88]|abstract[90]	new[88]|giv[90]	_	_
13-21	1573-1583	antibiotic	event[88]|substance|abstract[90]	new[88]|giv|giv[90]	_	_
13-22	1584-1595	prophylaxis	event[88]|abstract[90]	new[88]|giv[90]	_	_
13-23	1596-1599	for	event[88]|abstract[90]	new[88]|giv[90]	_	_
13-24	1600-1606	dental	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	coref	16-10[114_91]
13-25	1607-1617	procedures	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-26	1618-1620	in	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-27	1621-1629	low-risk	event[88]|abstract[90]|abstract[91]|abstract	new[88]|giv[90]|giv[91]|new	_	_
13-28	1630-1633	and	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-29	1634-1647	moderate-risk	event[88]|abstract[90]|abstract[91]|person[93]	new[88]|giv[90]|giv[91]|giv[93]	coref	13-37[94_93]
13-30	1648-1656	patients	event[88]|abstract[90]|abstract[91]|person[93]	new[88]|giv[90]|giv[91]|giv[93]	_	_
13-31	1657-1660	and	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-32	1661-1665	most	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-33	1666-1671	other	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-34	1672-1680	invasive	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-35	1681-1691	procedures	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-36	1692-1694	in	event[88]|abstract[90]|abstract[91]	new[88]|giv[90]|giv[91]	_	_
13-37	1695-1698	all	event[88]|abstract[90]|abstract[91]|person[94]	new[88]|giv[90]|giv[91]|giv[94]	coref	16-20[117_94]
13-38	1699-1707	patients	event[88]|abstract[90]|abstract[91]|person[94]	new[88]|giv[90]|giv[91]|giv[94]	_	_
13-39	1708-1709	.	_	_	_	_

#Text=A similar trend occurred in the United Kingdom , where a substantial increase in IE cases was reported after the introduction of these guidelines in 2008 .
14-1	1710-1711	A	abstract[95]	giv[95]	coref	19-7[138_95]
14-2	1712-1719	similar	abstract[95]	giv[95]	_	_
14-3	1720-1725	trend	abstract[95]	giv[95]	_	_
14-4	1726-1734	occurred	_	_	_	_
14-5	1735-1737	in	_	_	_	_
14-6	1738-1741	the	place[96]	new[96]	_	_
14-7	1742-1748	United	place[96]	new[96]	_	_
14-8	1749-1756	Kingdom	place[96]	new[96]	_	_
14-9	1757-1758	,	_	_	_	_
14-10	1759-1764	where	_	_	_	_
14-11	1765-1766	a	abstract[97]	giv[97]	_	_
14-12	1767-1778	substantial	abstract[97]	giv[97]	_	_
14-13	1779-1787	increase	abstract[97]	giv[97]	_	_
14-14	1788-1790	in	abstract[97]	giv[97]	_	_
14-15	1791-1793	IE	abstract[97]|object|abstract[99]	giv[97]|giv|new[99]	coref|coref|coref|coref	15-6[105_0]|20-13[149_99]|15-6[105_0]|20-13[149_99]
14-16	1794-1799	cases	abstract[97]|abstract[99]	giv[97]|new[99]	_	_
14-17	1800-1803	was	_	_	_	_
14-18	1804-1812	reported	_	_	_	_
14-19	1813-1818	after	_	_	_	_
14-20	1819-1822	the	event[100]	new[100]	_	_
14-21	1823-1835	introduction	event[100]	new[100]	_	_
14-22	1836-1838	of	event[100]	new[100]	_	_
14-23	1839-1844	these	event[100]|abstract[101]	new[100]|new[101]	_	_
14-24	1845-1855	guidelines	event[100]|abstract[101]	new[100]|new[101]	_	_
14-25	1856-1858	in	_	_	_	_
14-26	1859-1863	2008	time	new	_	_
14-27	1864-1865	.	_	_	_	_

#Text=We identified 45.9 % of all IE to be NIE , which is moderately higher than previous reports , accounting for 10 % to 30 % of all IE episodes .
15-1	1866-1868	We	person	giv	ana	17-2
15-2	1869-1879	identified	_	_	_	_
15-3	1880-1884	45.9	quantity[104]	new[104]	_	_
15-4	1885-1886	%	quantity[104]	new[104]	_	_
15-5	1887-1889	of	quantity[104]	new[104]	_	_
15-6	1890-1893	all	quantity[104]|object[105]	new[104]|giv[105]	coref	15-29[0_105]
15-7	1894-1896	IE	quantity[104]|object[105]	new[104]|giv[105]	_	_
15-8	1897-1899	to	_	_	_	_
15-9	1900-1902	be	_	_	_	_
15-10	1903-1906	NIE	abstract	giv	coref	20-26
15-11	1907-1908	,	_	_	_	_
15-12	1909-1914	which	_	_	_	_
15-13	1915-1917	is	_	_	_	_
15-14	1918-1928	moderately	_	_	_	_
15-15	1929-1935	higher	_	_	_	_
15-16	1936-1940	than	_	_	_	_
15-17	1941-1949	previous	abstract[107]	new[107]	_	_
15-18	1950-1957	reports	abstract[107]	new[107]	_	_
15-19	1958-1959	,	_	_	_	_
15-20	1960-1970	accounting	_	_	_	_
15-21	1971-1974	for	_	_	_	_
15-22	1975-1977	10	quantity[108]	new[108]	_	_
15-23	1978-1979	%	quantity[108]	new[108]	_	_
15-24	1980-1982	to	_	_	_	_
15-25	1983-1985	30	quantity[109]	new[109]	_	_
15-26	1986-1987	%	quantity[109]	new[109]	_	_
15-27	1988-1990	of	quantity[109]	new[109]	_	_
15-28	1991-1994	all	quantity[109]|abstract[111]	new[109]|giv[111]	_	_
15-29	1995-1997	IE	quantity[109]|object|abstract[111]	new[109]|giv|giv[111]	coref	19-22
15-30	1998-2006	episodes	quantity[109]|abstract[111]	new[109]|giv[111]	_	_
15-31	2007-2008	.	_	_	_	_

#Text=This finding might be related to the increment of invasive procedures , major incidence of degenerative valve disease in elderly patients , and longer intensive care unit and hospital stays .
16-1	2009-2013	This	abstract[112]	new[112]	_	_
16-2	2014-2021	finding	abstract[112]	new[112]	_	_
16-3	2022-2027	might	_	_	_	_
16-4	2028-2030	be	_	_	_	_
16-5	2031-2038	related	_	_	_	_
16-6	2039-2041	to	_	_	_	_
16-7	2042-2045	the	abstract[113]	new[113]	coref	20-28[155_113]
16-8	2046-2055	increment	abstract[113]	new[113]	_	_
16-9	2056-2058	of	abstract[113]	new[113]	_	_
16-10	2059-2067	invasive	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-11	2068-2078	procedures	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-12	2079-2080	,	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-13	2081-2086	major	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-14	2087-2096	incidence	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-15	2097-2099	of	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-16	2100-2112	degenerative	abstract[113]|abstract[114]|abstract[116]	new[113]|giv[114]|giv[116]	coref	21-21[171_116]
16-17	2113-2118	valve	abstract[113]|abstract[114]|object|abstract[116]	new[113]|giv[114]|new|giv[116]	_	_
16-18	2119-2126	disease	abstract[113]|abstract[114]|abstract[116]	new[113]|giv[114]|giv[116]	_	_
16-19	2127-2129	in	abstract[113]|abstract[114]|abstract[116]	new[113]|giv[114]|giv[116]	_	_
16-20	2130-2137	elderly	abstract[113]|abstract[114]|abstract[116]|person[117]	new[113]|giv[114]|giv[116]|giv[117]	coref	17-8[0_117]
16-21	2138-2146	patients	abstract[113]|abstract[114]|abstract[116]|person[117]	new[113]|giv[114]|giv[116]|giv[117]	_	_
16-22	2147-2148	,	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-23	2149-2152	and	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
16-24	2153-2159	longer	abstract[113]|abstract[114]|object[119]	new[113]|giv[114]|new[119]	_	_
16-25	2160-2169	intensive	abstract[113]|abstract[114]|object[119]	new[113]|giv[114]|new[119]	_	_
16-26	2170-2174	care	abstract[113]|abstract[114]|abstract|object[119]	new[113]|giv[114]|new|new[119]	_	_
16-27	2175-2179	unit	abstract[113]|abstract[114]|object[119]	new[113]|giv[114]|new[119]	_	_
16-28	2180-2183	and	_	_	_	_
16-29	2184-2192	hospital	place	new	_	_
16-30	2193-2198	stays	_	_	_	_
16-31	2199-2200	.	_	_	_	_

#Text=In our study , 24.5 % of patients underwent cardiac surgery during admission , which is similar to what has been reported in population-based studies from Italy and the United States .
17-1	2201-2203	In	_	_	_	_
17-2	2204-2207	our	person|event[122]	giv|new[122]	coref|ana|coref|ana	18-19[0_122]|20-19|18-19[0_122]|20-19
17-3	2208-2213	study	event[122]	new[122]	_	_
17-4	2214-2215	,	_	_	_	_
17-5	2216-2220	24.5	quantity[123]	new[123]	_	_
17-6	2221-2222	%	quantity[123]	new[123]	_	_
17-7	2223-2225	of	quantity[123]	new[123]	_	_
17-8	2226-2234	patients	quantity[123]|person	new[123]|giv	coref	19-20[142_0]
17-9	2235-2244	underwent	_	_	_	_
17-10	2245-2252	cardiac	event[125]	new[125]	_	_
17-11	2253-2260	surgery	event[125]	new[125]	_	_
17-12	2261-2267	during	_	_	_	_
17-13	2268-2277	admission	event	new	_	_
17-14	2278-2279	,	_	_	_	_
17-15	2280-2285	which	_	_	_	_
17-16	2286-2288	is	_	_	_	_
17-17	2289-2296	similar	_	_	_	_
17-18	2297-2299	to	_	_	_	_
17-19	2300-2304	what	_	_	_	_
17-20	2305-2308	has	_	_	_	_
17-21	2309-2313	been	_	_	_	_
17-22	2314-2322	reported	_	_	_	_
17-23	2323-2325	in	_	_	_	_
17-24	2326-2342	population-based	event[127]	giv[127]	_	_
17-25	2343-2350	studies	event[127]	giv[127]	_	_
17-26	2351-2355	from	event[127]	giv[127]	_	_
17-27	2356-2361	Italy	event[127]|place	giv[127]|new	_	_
17-28	2362-2365	and	event[127]	giv[127]	_	_
17-29	2366-2369	the	event[127]|place[129]	giv[127]|new[129]	coref	19-15[141_129]
17-30	2370-2376	United	event[127]|place[129]	giv[127]|new[129]	_	_
17-31	2377-2383	States	event[127]|place[129]	giv[127]|new[129]	_	_
17-32	2384-2385	.	_	_	_	_

#Text=In terms of gender , a major predominance of men was observed in comparison with women throughout the study period .
18-1	2386-2388	In	_	_	_	_
18-2	2389-2394	terms	_	_	_	_
18-3	2395-2397	of	_	_	_	_
18-4	2398-2404	gender	abstract	new	_	_
18-5	2405-2406	,	_	_	_	_
18-6	2407-2408	a	abstract[131]	new[131]	_	_
18-7	2409-2414	major	abstract[131]	new[131]	_	_
18-8	2415-2427	predominance	abstract[131]	new[131]	_	_
18-9	2428-2430	of	abstract[131]	new[131]	_	_
18-10	2431-2434	men	abstract[131]|person	new[131]|new	_	_
18-11	2435-2438	was	_	_	_	_
18-12	2439-2447	observed	_	_	_	_
18-13	2448-2450	in	_	_	_	_
18-14	2451-2461	comparison	abstract[133]	new[133]	_	_
18-15	2462-2466	with	abstract[133]	new[133]	_	_
18-16	2467-2472	women	abstract[133]|person[134]	new[133]|new[134]	ana	19-11[0_134]
18-17	2473-2483	throughout	abstract[133]|person[134]	new[133]|new[134]	_	_
18-18	2484-2487	the	abstract[133]|person[134]|abstract[136]	new[133]|new[134]|new[136]	coref	19-30[145_136]
18-19	2488-2493	study	abstract[133]|person[134]|event|abstract[136]	new[133]|new[134]|giv|new[136]	coref	19-31
18-20	2494-2500	period	abstract[133]|person[134]|abstract[136]	new[133]|new[134]|new[136]	_	_
18-21	2501-2502	.	_	_	_	_

#Text=Likewise , Toyoda et al. found a similar trend in their investigation conducted in the United States in which patients with IE were more likely to be male throughout the study period .
19-1	2503-2511	Likewise	_	_	_	_
19-2	2512-2513	,	_	_	_	_
19-3	2514-2520	Toyoda	person	new	coref	20-4
19-4	2521-2523	et	_	_	_	_
19-5	2524-2527	al.	_	_	_	_
19-6	2528-2533	found	_	_	_	_
19-7	2534-2535	a	abstract[138]	giv[138]	_	_
19-8	2536-2543	similar	abstract[138]	giv[138]	_	_
19-9	2544-2549	trend	abstract[138]	giv[138]	_	_
19-10	2550-2552	in	abstract[138]	giv[138]	_	_
19-11	2553-2558	their	abstract[138]|person|event[140]	giv[138]|giv|new[140]	_	_
19-12	2559-2572	investigation	abstract[138]|event[140]	giv[138]|new[140]	_	_
19-13	2573-2582	conducted	_	_	_	_
19-14	2583-2585	in	_	_	_	_
19-15	2586-2589	the	place[141]	giv[141]	_	_
19-16	2590-2596	United	place[141]	giv[141]	_	_
19-17	2597-2603	States	place[141]	giv[141]	_	_
19-18	2604-2606	in	_	_	_	_
19-19	2607-2612	which	_	_	_	_
19-20	2613-2621	patients	person[142]	giv[142]	coref	21-51[182_142]
19-21	2622-2626	with	person[142]	giv[142]	_	_
19-22	2627-2629	IE	person[142]|object	giv[142]|giv	coref	23-16
19-23	2630-2634	were	_	_	_	_
19-24	2635-2639	more	_	_	_	_
19-25	2640-2646	likely	_	_	_	_
19-26	2647-2649	to	_	_	_	_
19-27	2650-2652	be	_	_	_	_
19-28	2653-2657	male	_	_	_	_
19-29	2658-2668	throughout	_	_	_	_
19-30	2669-2672	the	time[145]	giv[145]	_	_
19-31	2673-2678	study	event|time[145]	giv|giv[145]	_	_
19-32	2679-2685	period	time[145]	giv[145]	_	_
19-33	2686-2687	.	_	_	_	_

#Text=In contrast with Toyoda et al. , who described a decline in the cases of nosocomial endocarditis , our findings highlight the paramount importance of NIE , the incidence of which steeply rose despite all the coordinated efforts to reduce hospital-acquired infections through mandatory continuous reporting , regulated interventions , or evidence-based consensus recommendations .
20-1	2688-2690	In	_	_	_	_
20-2	2691-2699	contrast	abstract[146]	new[146]	_	_
20-3	2700-2704	with	abstract[146]	new[146]	_	_
20-4	2705-2711	Toyoda	abstract[146]|person	new[146]|giv	coref	25-23
20-5	2712-2714	et	abstract[146]	new[146]	_	_
20-6	2715-2718	al.	abstract[146]	new[146]	_	_
20-7	2719-2720	,	_	_	_	_
20-8	2721-2724	who	_	_	_	_
20-9	2725-2734	described	_	_	_	_
20-10	2735-2736	a	event[148]	giv[148]	_	_
20-11	2737-2744	decline	event[148]	giv[148]	_	_
20-12	2745-2747	in	event[148]	giv[148]	_	_
20-13	2748-2751	the	event[148]|abstract[149]	giv[148]|giv[149]	_	_
20-14	2752-2757	cases	event[148]|abstract[149]	giv[148]|giv[149]	_	_
20-15	2758-2760	of	event[148]|abstract[149]	giv[148]|giv[149]	_	_
20-16	2761-2771	nosocomial	event[148]|abstract[149]|object[150]	giv[148]|giv[149]|new[150]	_	_
20-17	2772-2784	endocarditis	event[148]|abstract[149]|object[150]	giv[148]|giv[149]|new[150]	_	_
20-18	2785-2786	,	_	_	_	_
20-19	2787-2790	our	person|abstract[152]	giv|new[152]	coref|ana|coref|ana	25-27[214_152]|29-4|25-27[214_152]|29-4
20-20	2791-2799	findings	abstract[152]	new[152]	_	_
20-21	2800-2809	highlight	_	_	_	_
20-22	2810-2813	the	abstract[153]	new[153]	_	_
20-23	2814-2823	paramount	abstract[153]	new[153]	_	_
20-24	2824-2834	importance	abstract[153]	new[153]	_	_
20-25	2835-2837	of	abstract[153]	new[153]	_	_
20-26	2838-2841	NIE	abstract[153]|abstract	new[153]|giv	coref	21-53
20-27	2842-2843	,	_	_	_	_
20-28	2844-2847	the	abstract[155]	giv[155]	coref	27-1[236_155]
20-29	2848-2857	incidence	abstract[155]	giv[155]	_	_
20-30	2858-2860	of	_	_	_	_
20-31	2861-2866	which	_	_	_	_
20-32	2867-2874	steeply	_	_	_	_
20-33	2875-2879	rose	_	_	_	_
20-34	2880-2887	despite	_	_	_	_
20-35	2888-2891	all	event[156]	new[156]	_	_
20-36	2892-2895	the	event[156]	new[156]	_	_
20-37	2896-2907	coordinated	event[156]	new[156]	_	_
20-38	2908-2915	efforts	event[156]	new[156]	_	_
20-39	2916-2918	to	_	_	_	_
20-40	2919-2925	reduce	_	_	_	_
20-41	2926-2943	hospital-acquired	abstract[157]	giv[157]	coref	31-3[265_157]
20-42	2944-2954	infections	abstract[157]	giv[157]	_	_
20-43	2955-2962	through	abstract[157]	giv[157]	_	_
20-44	2963-2972	mandatory	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
20-45	2973-2983	continuous	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
20-46	2984-2993	reporting	abstract[157]|abstract[158]	giv[157]|new[158]	_	_
20-47	2994-2995	,	abstract[157]	giv[157]	_	_
20-48	2996-3005	regulated	abstract[157]|abstract[159]	giv[157]|new[159]	_	_
20-49	3006-3019	interventions	abstract[157]|abstract[159]	giv[157]|new[159]	_	_
20-50	3020-3021	,	abstract[157]	giv[157]	_	_
20-51	3022-3024	or	abstract[157]	giv[157]	_	_
20-52	3025-3039	evidence-based	abstract[157]|abstract[161]	giv[157]|new[161]	_	_
20-53	3040-3049	consensus	abstract[157]|abstract|abstract[161]	giv[157]|giv|new[161]	_	_
20-54	3050-3065	recommendations	abstract[157]|abstract[161]	giv[157]|new[161]	_	_
20-55	3066-3067	.	_	_	_	_

#Text=Concerning predisposing factors , a higher Charlson index ( reflecting more comorbidities such as diabetes mellitus , hemodialysis , coronary artery disease , peripheral artery disease , cancer , as well as major complications ranging from sepsis , shock , heart failure , and cerebrovascular disease ) were present in patients with NIE .
21-1	3068-3078	Concerning	_	_	_	_
21-2	3079-3091	predisposing	abstract[162]	giv[162]	_	_
21-3	3092-3099	factors	abstract[162]	giv[162]	_	_
21-4	3100-3101	,	abstract[162]	giv[162]	_	_
21-5	3102-3103	a	abstract[162]|abstract[164]	giv[162]|giv[164]	coref	21-18[0_164]
21-6	3104-3110	higher	abstract[162]|abstract[164]	giv[162]|giv[164]	_	_
21-7	3111-3119	Charlson	abstract[162]|person|abstract[164]	giv[162]|new|giv[164]	_	_
21-8	3120-3125	index	abstract[162]|abstract[164]	giv[162]|giv[164]	_	_
21-9	3126-3127	(	_	_	_	_
21-10	3128-3138	reflecting	_	_	_	_
21-11	3139-3143	more	abstract[165]	new[165]	_	_
21-12	3144-3157	comorbidities	abstract[165]	new[165]	_	_
21-13	3158-3162	such	abstract[165]	new[165]	_	_
21-14	3163-3165	as	abstract[165]	new[165]	_	_
21-15	3166-3174	diabetes	abstract[165]|abstract|abstract[167]	new[165]|new|new[167]	_	_
21-16	3175-3183	mellitus	abstract[165]|abstract[167]	new[165]|new[167]	_	_
21-17	3184-3185	,	abstract[165]	new[165]	_	_
21-18	3186-3198	hemodialysis	abstract[165]|abstract	new[165]|giv	_	_
21-19	3199-3200	,	abstract[165]	new[165]	_	_
21-20	3201-3209	coronary	abstract[165]|person	new[165]|new	_	_
21-21	3210-3216	artery	abstract[165]|object|abstract[171]	new[165]|new|giv[171]	coref|coref|coref|coref	21-25|21-24[173_171]|21-25|21-24[173_171]
21-22	3217-3224	disease	abstract[165]|abstract[171]	new[165]|giv[171]	_	_
21-23	3225-3226	,	abstract[165]	new[165]	_	_
21-24	3227-3237	peripheral	abstract[165]|abstract[173]	new[165]|giv[173]	coref	21-45[181_173]
21-25	3238-3244	artery	abstract[165]|object|abstract[173]	new[165]|giv|giv[173]	_	_
21-26	3245-3252	disease	abstract[165]|abstract[173]	new[165]|giv[173]	_	_
21-27	3253-3254	,	abstract[165]	new[165]	_	_
21-28	3255-3261	cancer	abstract[165]|abstract	new[165]|new	_	_
21-29	3262-3263	,	abstract[165]	new[165]	_	_
21-30	3264-3266	as	abstract[165]	new[165]	_	_
21-31	3267-3271	well	abstract[165]	new[165]	_	_
21-32	3272-3274	as	abstract[165]	new[165]	_	_
21-33	3275-3280	major	abstract[165]|abstract[175]	new[165]|new[175]	coref	24-24[202_175]
21-34	3281-3294	complications	abstract[165]|abstract[175]	new[165]|new[175]	_	_
21-35	3295-3302	ranging	_	_	_	_
21-36	3303-3307	from	_	_	_	_
21-37	3308-3314	sepsis	abstract	new	_	_
21-38	3315-3316	,	_	_	_	_
21-39	3317-3322	shock	event	giv	_	_
21-40	3323-3324	,	_	_	_	_
21-41	3325-3330	heart	object|abstract[179]	giv|giv[179]	_	_
21-42	3331-3338	failure	abstract[179]	giv[179]	_	_
21-43	3339-3340	,	_	_	_	_
21-44	3341-3344	and	_	_	_	_
21-45	3345-3360	cerebrovascular	abstract|abstract[181]	new|giv[181]	_	_
21-46	3361-3368	disease	abstract[181]	giv[181]	_	_
21-47	3369-3370	)	_	_	_	_
21-48	3371-3375	were	_	_	_	_
21-49	3376-3383	present	_	_	_	_
21-50	3384-3386	in	_	_	_	_
21-51	3387-3395	patients	person[182]	giv[182]	_	_
21-52	3396-3400	with	person[182]	giv[182]	_	_
21-53	3401-3404	NIE	person[182]|abstract	giv[182]|giv	coref	22-21
21-54	3405-3406	.	_	_	_	_

#Text=This rise in underlying diseases might be related to the aging of the population and explains why those adults with NIE , especially those older than age 80 years , depicted the lowest survival rates .
22-1	3407-3411	This	event[184]	giv[184]	_	_
22-2	3412-3416	rise	event[184]	giv[184]	_	_
22-3	3417-3419	in	event[184]	giv[184]	_	_
22-4	3420-3430	underlying	event[184]|abstract[185]	giv[184]|new[185]	_	_
22-5	3431-3439	diseases	event[184]|abstract[185]	giv[184]|new[185]	_	_
22-6	3440-3445	might	_	_	_	_
22-7	3446-3448	be	_	_	_	_
22-8	3449-3456	related	_	_	_	_
22-9	3457-3459	to	_	_	_	_
22-10	3460-3463	the	abstract[186]	new[186]	_	_
22-11	3464-3469	aging	abstract[186]	new[186]	_	_
22-12	3470-3472	of	abstract[186]	new[186]	_	_
22-13	3473-3476	the	abstract[186]|abstract[187]	new[186]|new[187]	_	_
22-14	3477-3487	population	abstract[186]|abstract[187]	new[186]|new[187]	_	_
22-15	3488-3491	and	_	_	_	_
22-16	3492-3500	explains	_	_	_	_
22-17	3501-3504	why	_	_	_	_
22-18	3505-3510	those	person[188]	new[188]	_	_
22-19	3511-3517	adults	person[188]	new[188]	_	_
22-20	3518-3522	with	person[188]	new[188]	_	_
22-21	3523-3526	NIE	person[188]|abstract	new[188]|giv	_	_
22-22	3527-3528	,	_	_	_	_
22-23	3529-3539	especially	_	_	_	_
22-24	3540-3545	those	_	_	_	_
22-25	3546-3551	older	_	_	_	_
22-26	3552-3556	than	_	_	_	_
22-27	3557-3560	age	abstract	new	_	_
22-28	3561-3563	80	time[191]	giv[191]	_	_
22-29	3564-3569	years	time[191]	giv[191]	_	_
22-30	3570-3571	,	_	_	_	_
22-31	3572-3580	depicted	_	_	_	_
22-32	3581-3584	the	abstract[193]	giv[193]	coref	24-21[201_193]
22-33	3585-3591	lowest	abstract[193]	giv[193]	_	_
22-34	3592-3600	survival	event|abstract[193]	new|giv[193]	_	_
22-35	3601-3606	rates	abstract[193]	giv[193]	_	_
22-36	3607-3608	.	_	_	_	_

#Text=Regarding the microbiological profile , Gram-positive pathogens are still the most frequent microorganisms associated with IE , as previously reported in other series .
23-1	3609-3618	Regarding	_	_	_	_
23-2	3619-3622	the	abstract[194]	new[194]	_	_
23-3	3623-3638	microbiological	abstract[194]	new[194]	_	_
23-4	3639-3646	profile	abstract[194]	new[194]	_	_
23-5	3647-3648	,	_	_	_	_
23-6	3649-3662	Gram-positive	abstract[195]	new[195]	coref	23-9[196_195]
23-7	3663-3672	pathogens	abstract[195]	new[195]	_	_
23-8	3673-3676	are	_	_	_	_
23-9	3677-3682	still	abstract[196]	giv[196]	coref	24-1[199_196]
23-10	3683-3686	the	abstract[196]	giv[196]	_	_
23-11	3687-3691	most	abstract[196]	giv[196]	_	_
23-12	3692-3700	frequent	abstract[196]	giv[196]	_	_
23-13	3701-3715	microorganisms	abstract[196]	giv[196]	_	_
23-14	3716-3726	associated	_	_	_	_
23-15	3727-3731	with	_	_	_	_
23-16	3732-3734	IE	object	giv	coref	24-49[207_0]
23-17	3735-3736	,	_	_	_	_
23-18	3737-3739	as	_	_	_	_
23-19	3740-3750	previously	_	_	_	_
23-20	3751-3759	reported	_	_	_	_
23-21	3760-3762	in	_	_	_	_
23-22	3763-3768	other	abstract[198]	new[198]	_	_
23-23	3769-3775	series	abstract[198]	new[198]	_	_
23-24	3776-3777	.	_	_	_	_

#Text=These microorganisms often have a healthcare-associated origin , widely recognized as virulent and resistant organisms , and are related to high rates of complications and high mortality rates . Selton-Suty et al. demonstrated Staphylococcus aureus as the only factor associated with a higher risk of in-hospital mortality in healthcare-associated IE .
24-1	3778-3783	These	abstract[199]	giv[199]	coref	25-15[212_199]
24-2	3784-3798	microorganisms	abstract[199]	giv[199]	_	_
24-3	3799-3804	often	_	_	_	_
24-4	3805-3809	have	_	_	_	_
24-5	3810-3811	a	abstract[200]	new[200]	_	_
24-6	3812-3833	healthcare-associated	abstract[200]	new[200]	_	_
24-7	3834-3840	origin	abstract[200]	new[200]	_	_
24-8	3841-3842	,	_	_	_	_
24-9	3843-3849	widely	_	_	_	_
24-10	3850-3860	recognized	_	_	_	_
24-11	3861-3863	as	_	_	_	_
24-12	3864-3872	virulent	_	_	_	_
24-13	3873-3876	and	_	_	_	_
24-14	3877-3886	resistant	_	_	_	_
24-15	3887-3896	organisms	_	_	_	_
24-16	3897-3898	,	_	_	_	_
24-17	3899-3902	and	_	_	_	_
24-18	3903-3906	are	_	_	_	_
24-19	3907-3914	related	_	_	_	_
24-20	3915-3917	to	_	_	_	_
24-21	3918-3922	high	abstract[201]	giv[201]	coref	29-18[256_201]
24-22	3923-3928	rates	abstract[201]	giv[201]	_	_
24-23	3929-3931	of	abstract[201]	giv[201]	_	_
24-24	3932-3945	complications	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
24-25	3946-3949	and	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
24-26	3950-3954	high	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
24-27	3955-3964	mortality	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
24-28	3965-3970	rates	abstract[201]|abstract[202]	giv[201]|giv[202]	_	_
24-29	3971-3972	.	_	_	_	_
24-30	3973-3984	Selton-Suty	person	new	_	_
24-31	3985-3987	et	_	_	_	_
24-32	3988-3991	al.	_	_	_	_
24-33	3992-4004	demonstrated	_	_	_	_
24-34	4005-4019	Staphylococcus	_	_	_	_
24-35	4020-4026	aureus	_	_	_	_
24-36	4027-4029	as	_	_	_	_
24-37	4030-4033	the	abstract[204]	giv[204]	_	_
24-38	4034-4038	only	abstract[204]	giv[204]	_	_
24-39	4039-4045	factor	abstract[204]	giv[204]	_	_
24-40	4046-4056	associated	_	_	_	_
24-41	4057-4061	with	_	_	_	_
24-42	4062-4063	a	abstract[205]	giv[205]	_	_
24-43	4064-4070	higher	abstract[205]	giv[205]	_	_
24-44	4071-4075	risk	abstract[205]	giv[205]	_	_
24-45	4076-4078	of	abstract[205]	giv[205]	_	_
24-46	4079-4090	in-hospital	abstract[205]|abstract[206]	giv[205]|giv[206]	coref	25-11[0_206]
24-47	4091-4100	mortality	abstract[205]|abstract[206]	giv[205]|giv[206]	_	_
24-48	4101-4103	in	abstract[205]|abstract[206]	giv[205]|giv[206]	_	_
24-49	4104-4125	healthcare-associated	abstract[205]|abstract[206]|object[207]	giv[205]|giv[206]|giv[207]	coref	27-3[0_207]
24-50	4126-4128	IE	abstract[205]|abstract[206]|object[207]	giv[205]|giv[206]|giv[207]	_	_
24-51	4129-4130	.	_	_	_	_

#Text=Compared with fungi , anaerobic , and streptococcal infection , mortality was higher for Gram-positive and Gram-negative pathogens , which differs from Toyoda et al. ’ s findings .
25-1	4131-4139	Compared	_	_	_	_
25-2	4140-4144	with	_	_	_	_
25-3	4145-4150	fungi	plant	new	_	_
25-4	4151-4152	,	_	_	_	_
25-5	4153-4162	anaerobic	substance	new	_	_
25-6	4163-4164	,	_	_	_	_
25-7	4165-4168	and	_	_	_	_
25-8	4169-4182	streptococcal	abstract[210]	new[210]	_	_
25-9	4183-4192	infection	abstract[210]	new[210]	_	_
25-10	4193-4194	,	_	_	_	_
25-11	4195-4204	mortality	abstract	giv	_	_
25-12	4205-4208	was	_	_	_	_
25-13	4209-4215	higher	_	_	_	_
25-14	4216-4219	for	_	_	_	_
25-15	4220-4233	Gram-positive	abstract[212]	giv[212]	_	_
25-16	4234-4237	and	abstract[212]	giv[212]	_	_
25-17	4238-4251	Gram-negative	abstract[212]	giv[212]	_	_
25-18	4252-4261	pathogens	abstract[212]	giv[212]	_	_
25-19	4262-4263	,	_	_	_	_
25-20	4264-4269	which	_	_	_	_
25-21	4270-4277	differs	_	_	_	_
25-22	4278-4282	from	_	_	_	_
25-23	4283-4289	Toyoda	person	giv	_	_
25-24	4290-4292	et	_	_	_	_
25-25	4293-4296	al.	_	_	_	_
25-26	4297-4298	’	_	_	_	_
25-27	4299-4300	s	abstract[214]	giv[214]	coref	28-1[246_214]
25-28	4301-4309	findings	abstract[214]	giv[214]	_	_
25-29	4310-4311	.	_	_	_	_

#Text=Spain ’s climate varies across its geography , resulting in three broad regions : the North , where Atlantic weather characterized by a large proportion of humid days and the prevalence of precipitation ; the Center , distinguished by a continental plateau with less precipitation ; and the South , which is characterized by a Mediterranean climate with almost no precipitation , higher temperatures , and longer , sunny days .
26-1	4312-4317	Spain	place[215]|abstract[216]	giv[215]|new[216]	ana|coref|ana|coref	26-6[0_215]|26-55[231_216]|26-6[0_215]|26-55[231_216]
26-2	4318-4320	’s	place[215]|abstract[216]	giv[215]|new[216]	_	_
26-3	4321-4328	climate	abstract[216]	new[216]	_	_
26-4	4329-4335	varies	_	_	_	_
26-5	4336-4342	across	_	_	_	_
26-6	4343-4346	its	place|abstract[218]	giv|new[218]	coref|coref	27-28|27-28
26-7	4347-4356	geography	abstract[218]	new[218]	_	_
26-8	4357-4358	,	_	_	_	_
26-9	4359-4368	resulting	_	_	_	_
26-10	4369-4371	in	_	_	_	_
26-11	4372-4377	three	place[219]	new[219]	coref	27-25[244_219]
26-12	4378-4383	broad	place[219]	new[219]	_	_
26-13	4384-4391	regions	place[219]	new[219]	_	_
26-14	4392-4393	:	_	_	_	_
26-15	4394-4397	the	place[220]	giv[220]	coref	27-7[0_220]
26-16	4398-4403	North	place[220]	giv[220]	_	_
26-17	4404-4405	,	_	_	_	_
26-18	4406-4411	where	_	_	_	_
26-19	4412-4420	Atlantic	abstract[221]	new[221]	coref	31-11[0_221]
26-20	4421-4428	weather	abstract[221]	new[221]	_	_
26-21	4429-4442	characterized	_	_	_	_
26-22	4443-4445	by	_	_	_	_
26-23	4446-4447	a	quantity[222]	new[222]	_	_
26-24	4448-4453	large	quantity[222]	new[222]	_	_
26-25	4454-4464	proportion	quantity[222]	new[222]	_	_
26-26	4465-4467	of	quantity[222]	new[222]	_	_
26-27	4468-4473	humid	quantity[222]|time[223]	new[222]|new[223]	_	_
26-28	4474-4478	days	quantity[222]|time[223]	new[222]|new[223]	_	_
26-29	4479-4482	and	_	_	_	_
26-30	4483-4486	the	abstract[224]	new[224]	_	_
26-31	4487-4497	prevalence	abstract[224]	new[224]	_	_
26-32	4498-4500	of	abstract[224]	new[224]	_	_
26-33	4501-4514	precipitation	abstract[224]|substance	new[224]|new	coref	26-44[229_0]
26-34	4515-4516	;	_	_	_	_
26-35	4517-4520	the	place[226]|place[227]	new[226]|new[227]	coref|coref|coref|coref	27-22[241_226]|27-22[242_227]|27-22[241_226]|27-22[242_227]
26-36	4521-4527	Center	place[226]|place[227]	new[226]|new[227]	_	_
26-37	4528-4529	,	place[227]	new[227]	_	_
26-38	4530-4543	distinguished	place[227]	new[227]	_	_
26-39	4544-4546	by	place[227]	new[227]	_	_
26-40	4547-4548	a	place[227]|place[228]	new[227]|new[228]	_	_
26-41	4549-4560	continental	place[227]|place[228]	new[227]|new[228]	_	_
26-42	4561-4568	plateau	place[227]|place[228]	new[227]|new[228]	_	_
26-43	4569-4573	with	place[227]|place[228]	new[227]|new[228]	_	_
26-44	4574-4578	less	place[227]|place[228]|substance[229]	new[227]|new[228]|giv[229]	coref	26-59[232_229]
26-45	4579-4592	precipitation	place[227]|place[228]|substance[229]	new[227]|new[228]|giv[229]	_	_
26-46	4593-4594	;	place[227]	new[227]	_	_
26-47	4595-4598	and	place[227]	new[227]	_	_
26-48	4599-4602	the	place[227]|place[230]	new[227]|new[230]	coref	27-25[0_230]
26-49	4603-4608	South	place[227]|place[230]	new[227]|new[230]	_	_
26-50	4609-4610	,	_	_	_	_
26-51	4611-4616	which	_	_	_	_
26-52	4617-4619	is	_	_	_	_
26-53	4620-4633	characterized	_	_	_	_
26-54	4634-4636	by	_	_	_	_
26-55	4637-4638	a	abstract[231]	giv[231]	_	_
26-56	4639-4652	Mediterranean	abstract[231]	giv[231]	_	_
26-57	4653-4660	climate	abstract[231]	giv[231]	_	_
26-58	4661-4665	with	abstract[231]	giv[231]	_	_
26-59	4666-4672	almost	abstract[231]|substance[232]	giv[231]|giv[232]	_	_
26-60	4673-4675	no	abstract[231]|substance[232]	giv[231]|giv[232]	_	_
26-61	4676-4689	precipitation	abstract[231]|substance[232]	giv[231]|giv[232]	_	_
26-62	4690-4691	,	abstract[231]	giv[231]	_	_
26-63	4692-4698	higher	abstract[231]|abstract[233]	giv[231]|new[233]	_	_
26-64	4699-4711	temperatures	abstract[231]|abstract[233]	giv[231]|new[233]	_	_
26-65	4712-4713	,	abstract[231]	giv[231]	_	_
26-66	4714-4717	and	abstract[231]	giv[231]	_	_
26-67	4718-4724	longer	abstract[231]	giv[231]	_	_
26-68	4725-4726	,	abstract[231]	giv[231]	_	_
26-69	4727-4732	sunny	abstract[231]|time[234]	giv[231]|new[234]	_	_
26-70	4733-4737	days	abstract[231]|time[234]	giv[231]|new[234]	_	_
26-71	4738-4739	.	_	_	_	_

#Text=The higher IE incidence in the North region may be due to the higher level of humidity experienced there compared to the Center or South regions of Spain .
27-1	4740-4743	The	abstract[236]	giv[236]	_	_
27-2	4744-4750	higher	abstract[236]	giv[236]	_	_
27-3	4751-4753	IE	object|abstract[236]	giv|giv[236]	coref	29-18
27-4	4754-4763	incidence	abstract[236]	giv[236]	_	_
27-5	4764-4766	in	abstract[236]	giv[236]	_	_
27-6	4767-4770	the	abstract[236]|place[238]	giv[236]|new[238]	_	_
27-7	4771-4776	North	abstract[236]|place|place[238]	giv[236]|giv|new[238]	_	_
27-8	4777-4783	region	abstract[236]|place[238]	giv[236]|new[238]	_	_
27-9	4784-4787	may	_	_	_	_
27-10	4788-4790	be	_	_	_	_
27-11	4791-4794	due	_	_	_	_
27-12	4795-4797	to	_	_	_	_
27-13	4798-4801	the	abstract[239]	new[239]	_	_
27-14	4802-4808	higher	abstract[239]	new[239]	_	_
27-15	4809-4814	level	abstract[239]	new[239]	_	_
27-16	4815-4817	of	abstract[239]	new[239]	_	_
27-17	4818-4826	humidity	abstract[239]|substance	new[239]|new	coref	30-14[261_0]
27-18	4827-4838	experienced	_	_	_	_
27-19	4839-4844	there	_	_	_	_
27-20	4845-4853	compared	_	_	_	_
27-21	4854-4856	to	_	_	_	_
27-22	4857-4860	the	place[241]|place[242]	giv[241]|giv[242]	_	_
27-23	4861-4867	Center	place[241]|place[242]	giv[241]|giv[242]	_	_
27-24	4868-4870	or	place[242]	giv[242]	_	_
27-25	4871-4876	South	place[242]|place|place[244]	giv[242]|giv|giv[244]	_	_
27-26	4877-4884	regions	place[242]|place[244]	giv[242]|giv[244]	_	_
27-27	4885-4887	of	place[242]|place[244]	giv[242]|giv[244]	_	_
27-28	4888-4893	Spain	place[242]|place[244]|place	giv[242]|giv[244]|giv	_	_
27-29	4894-4895	.	_	_	_	_

#Text=These findings emphasized the importance of the site of acquisition .
28-1	4896-4901	These	abstract[246]	giv[246]	coref	30-4[260_246]
28-2	4902-4910	findings	abstract[246]	giv[246]	_	_
28-3	4911-4921	emphasized	_	_	_	_
28-4	4922-4925	the	abstract[247]	new[247]	ana	29-7[0_247]
28-5	4926-4936	importance	abstract[247]	new[247]	_	_
28-6	4937-4939	of	abstract[247]	new[247]	_	_
28-7	4940-4943	the	abstract[247]|place[248]	new[247]|new[248]	_	_
28-8	4944-4948	site	abstract[247]|place[248]	new[247]|new[248]	_	_
28-9	4949-4951	of	abstract[247]|place[248]	new[247]|new[248]	_	_
28-10	4952-4963	acquisition	abstract[247]|place[248]|event	new[247]|new[248]|new	_	_
28-11	4964-4965	.	_	_	_	_

#Text=Indeed , to our knowledge , this is the first study to report a significant difference in IE rates in terms of location .
29-1	4966-4972	Indeed	_	_	_	_
29-2	4973-4974	,	_	_	_	_
29-3	4975-4977	to	_	_	_	_
29-4	4978-4981	our	person|abstract[251]	giv|new[251]	_	_
29-5	4982-4991	knowledge	abstract[251]	new[251]	_	_
29-6	4992-4993	,	_	_	_	_
29-7	4994-4998	this	abstract	giv	coref	29-9[253_0]
29-8	4999-5001	is	_	_	_	_
29-9	5002-5005	the	abstract[253]	giv[253]	_	_
29-10	5006-5011	first	abstract[253]	giv[253]	_	_
29-11	5012-5017	study	abstract[253]	giv[253]	_	_
29-12	5018-5020	to	_	_	_	_
29-13	5021-5027	report	_	_	_	_
29-14	5028-5029	a	abstract[254]	new[254]	_	_
29-15	5030-5041	significant	abstract[254]	new[254]	_	_
29-16	5042-5052	difference	abstract[254]	new[254]	_	_
29-17	5053-5055	in	abstract[254]	new[254]	_	_
29-18	5056-5058	IE	abstract[254]|object|abstract[256]	new[254]|giv|giv[256]	_	_
29-19	5059-5064	rates	abstract[254]|abstract[256]	new[254]|giv[256]	_	_
29-20	5065-5067	in	abstract[254]|abstract[256]	new[254]|giv[256]	_	_
29-21	5068-5073	terms	abstract[254]|abstract[256]	new[254]|giv[256]	_	_
29-22	5074-5076	of	abstract[254]|abstract[256]	new[254]|giv[256]	_	_
29-23	5077-5085	location	abstract[254]|abstract[256]|abstract	new[254]|giv[256]|new	ana	30-1
29-24	5086-5087	.	_	_	_	_

#Text=This corresponds with Blanco et al. ’ s findings , who demonstrated that increasing humidity is associated with greater Staphylococcus aureus colonization .
30-1	5088-5092	This	abstract	giv	_	_
30-2	5093-5104	corresponds	_	_	_	_
30-3	5105-5109	with	_	_	_	_
30-4	5110-5116	Blanco	person|abstract[260]	new|giv[260]	_	_
30-5	5117-5119	et	abstract[260]	giv[260]	_	_
30-6	5120-5123	al.	abstract[260]	giv[260]	_	_
30-7	5124-5125	’	abstract[260]	giv[260]	_	_
30-8	5126-5127	s	abstract[260]	giv[260]	_	_
30-9	5128-5136	findings	abstract[260]	giv[260]	_	_
30-10	5137-5138	,	_	_	_	_
30-11	5139-5142	who	_	_	_	_
30-12	5143-5155	demonstrated	_	_	_	_
30-13	5156-5160	that	_	_	_	_
30-14	5161-5171	increasing	substance[261]	giv[261]	coref	31-22[0_261]
30-15	5172-5180	humidity	substance[261]	giv[261]	_	_
30-16	5181-5183	is	_	_	_	_
30-17	5184-5194	associated	_	_	_	_
30-18	5195-5199	with	_	_	_	_
30-19	5200-5207	greater	abstract[263]	new[263]	_	_
30-20	5208-5222	Staphylococcus	place|abstract[263]	giv|new[263]	coref	31-24
30-21	5223-5229	aureus	abstract[263]	new[263]	_	_
30-22	5230-5242	colonization	abstract[263]	new[263]	_	_
30-23	5243-5244	.	_	_	_	_

#Text=Certainly , Staphylococcus aureus infections are more common in humid weather conditions . Wang et al. reported a similar correlation between humidity and Staphylococcus aureus infections .
31-1	5245-5254	Certainly	_	_	_	_
31-2	5255-5256	,	_	_	_	_
31-3	5257-5271	Staphylococcus	abstract[265]	giv[265]	coref	31-24[273_265]
31-4	5272-5278	aureus	object|abstract[265]	new|giv[265]	coref	31-25
31-5	5279-5289	infections	abstract[265]	giv[265]	_	_
31-6	5290-5293	are	_	_	_	_
31-7	5294-5298	more	_	_	_	_
31-8	5299-5305	common	_	_	_	_
31-9	5306-5308	in	_	_	_	_
31-10	5309-5314	humid	abstract[267]	new[267]	_	_
31-11	5315-5322	weather	abstract|abstract[267]	giv|new[267]	_	_
31-12	5323-5333	conditions	abstract[267]	new[267]	_	_
31-13	5334-5335	.	_	_	_	_
31-14	5336-5340	Wang	person	new	_	_
31-15	5341-5343	et	_	_	_	_
31-16	5344-5347	al.	_	_	_	_
31-17	5348-5356	reported	_	_	_	_
31-18	5357-5358	a	abstract[269]	new[269]	_	_
31-19	5359-5366	similar	abstract[269]	new[269]	_	_
31-20	5367-5378	correlation	abstract[269]	new[269]	_	_
31-21	5379-5386	between	abstract[269]	new[269]	_	_
31-22	5387-5395	humidity	abstract[269]|substance	new[269]|giv	_	_
31-23	5396-5399	and	abstract[269]	new[269]	_	_
31-24	5400-5414	Staphylococcus	abstract[269]|object|abstract[273]	new[269]|giv|giv[273]	_	_
31-25	5415-5421	aureus	abstract[269]|object|abstract[273]	new[269]|giv|giv[273]	_	_
31-26	5422-5432	infections	abstract[269]|abstract[273]	new[269]|giv[273]	_	_
31-27	5433-5434	.	_	_	_	_
